Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) - Total Assets
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) holds total assets worth $128.50 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EPRX total equity for net asset value and shareholders' equity analysis.
Eupraxia Pharmaceuticals Inc. Common Stock - Total Assets Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Eupraxia Pharmaceuticals Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Eupraxia Pharmaceuticals Inc. Common Stock's total assets of $128.50 Million consist of 98.6% current assets and 1.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.7% |
| Accounts Receivable | $228.87K | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EPRX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eupraxia Pharmaceuticals Inc. Common Stock's current assets represent 98.6% of total assets in 2024, an increase from 92.8% in 2017.
- Cash Position: Cash and equivalents constituted 94.7% of total assets in 2024, up from 68.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Eupraxia Pharmaceuticals Inc. Common Stock Competitors by Total Assets
Key competitors of Eupraxia Pharmaceuticals Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Eupraxia Pharmaceuticals Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.98 | 4.17 | 0.05 |
| Quick Ratio | 23.98 | 4.17 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $121.88 Million | $7.52 Million | $-21.40 Million |
Eupraxia Pharmaceuticals Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Eupraxia Pharmaceuticals Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.00 |
| Latest Market Cap to Assets Ratio | 13.15 |
| Asset Growth Rate (YoY) | 72.4% |
| Total Assets | $34.94 Million |
| Market Capitalization | $459.64 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Eupraxia Pharmaceuticals Inc. Common Stock's assets at a significant premium (13.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eupraxia Pharmaceuticals Inc. Common Stock's assets grew by 72.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
The table below shows the annual total assets of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $34.94 Million | +72.42% |
| 2023-12-31 | $20.27 Million | -21.72% |
| 2022-12-31 | $25.89 Million | -17.08% |
| 2021-12-31 | $31.22 Million | +2047.93% |
| 2020-12-31 | $1.45 Million | -55.75% |
| 2019-12-31 | $3.29 Million | +12.92% |
| 2018-12-31 | $2.91 Million | -50.20% |
| 2017-12-31 | $5.84 Million | -- |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more